RNA · Atrium Therapeutics, Inc.
$11.57
-0.69% last session
End-of-day data · updated 2026-07-29
Market cap
$0B
Enterprise value
$0B
Trailing P/E
—
Forward P/E
-2.0
Dividend yield
—
Beta
—
Avg volume
0M
Employees
—
2D change
-0.69%
5D change
—
10D change
-5.43%
30D change
-15.82%
60D change
-11.62%
MTD change
-13.61%
YTD change
—
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RNA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-18
Latest call per bank · past 12 months
Wells Fargo
Overweight$25.00
+116.1% vs priceRBC Capital
Sector Perform$72.00
+522.3% vs priceCitigroup
Neutral$72.00
+522.3% vs priceBank of America
Buy$65.00
+461.8% vs priceBarclays
Overweight$62.00
+435.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-18 | Cantor Fitzgerald | Initiates | Overweight | $0.00 → $25.00 |
| 2026-05-15 | Leerink Partners | Initiates | Outperform | $0.00 → $25.00 |
| 2026-03-11 | Wells Fargo | Initiates | Overweight | $0.00 → $25.00 |
| 2025-11-11 | Chardan Capital | Maintains | Neutral | $72.00 |
| 2025-10-29 | TD Cowen | Downgrade | Buy → Hold | $78.00 → $74.00 |
| 2025-10-28 | Chardan Capital | Downgrade | Buy → Neutral | $75.00 → $72.00 |
| 2025-10-28 | RBC Capital | Downgrade | Outperform → Sector Perform | $61.00 → $72.00 |
| 2025-10-27 | Citigroup | Downgrade | Buy → Neutral | $75.00 → $72.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 8.9% below the 50-day MA ($12.62).
- MACD (12,26,9): MACD histogram is negative (-0.11) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($11.49).
RNA Price Chart
Loading chart for RNA…
Fundamentals
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$124B 8.2% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$73B -9.7% YTD
ARGX
argenx SE
$55B 3.7% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$39B -27.5% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.8% YTD
RPRX
Royalty Pharma plc
$35B 56.7% YTD
ONC
BeOne Medicines Ltd.
$34B 8.8% YTD
INCY
Incyte Corporation
$26B 31.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.